Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 3;8:237. doi: 10.3389/fphar.2017.00237

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Sims, Singh, Mu, Gokden, Zakaria, Nguyen and Mayeux.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of rolipram on renal microvascular perfusion. A dose-finding study (A) was used to determine the efficacy of rolipram to prevent the decline in renal cortical microvascular perfusion. Rolipram was administered at the time of CLP (ip injection) and perfusion was measured at 6 h; n = 5 for Sham; n = 8 for CLP; n = 5–8 for CLP + Rolipram; ^∗p < 0.05 compared to Sham by two-way ANOVA; ^#this dose produced 70% lethality. The dose of 0.1 mg/kg was the lowest dose to prevent both the decline in vessels with continuous flow and the increase in vessels with no flow. Next, rolipram (0.1 mg/kg, ip) was administered at 6 h post-CLP and perfusion was measured at 18 h (B). Even with delayed administration, rolipram protected renal microvascular perfusion; ^∗p < 0.05 compared to Sham and CLP + Rolipram; ^#p < 0.05 compared to Sham and CLP; n = 5 for 18 h Sham; n = 6 for 18 h CLP; n = 5 for 18 h CLP + Rolipram.